Recent Articles from Investor Brand Network

Disseminated on behalf of Canamera Energy Metals Corp. (CSE: EMET) (OTCQB: EMETF) and may include paid advertising.

MindWave Innovations (NYSE American: APUS) is positioning as bitcoin moves deeper into corporate finance and many companies contemplate not whether digital assets belong on the balance sheet but rather how they can be held, reported and deployed responsibly. “MindWave provides a secure and compliant gateway to digital assets through insured custody solutions, AI-enabled yield strategies and transparent reporting systems. That combination is important because corporate adoption depends not only on asset exposure but also on the ability to demonstrate that treasury activity is documented and aligned with the expectations of directors, auditors and shareholders,” reads a recent article.

Oncotelic Therapeutics (OTCQB: OTLC) was featured in a recent article that discussed the company’s efforts to move beyond its roots as a clinical-stage biotechnology company into the quickly expanding intersection of artificial intelligence and industrial automation. The publication reads, “Through two closely aligned announcements, the firm has unveiled a strategic partnership with TechForce Robotics, which positions it to commercialize a next-generation, AI-enhanced platform created for regulated pharmaceutical environments… At the core of this pivot is Oncotelic’s proprietary PDAOAI platform, an AI-driven system designed to improve compliance, monitoring, and operational intelligence. By integrating this innovation with TechForce Robotics’ hardware and manufacturing expertise, the companies aim to deliver a GMP-compliant robotics solution capable of automating critical workflows in pharmaceutical production and laboratory settings.”

VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, has announced new in vitro proof-of-concept data supporting its BiTAC-ADC platform, a technology designed to improve the selectivity of antibody-drug conjugates in cancer treatment. The announcement comes as the company prepares to engage with potential pharmaceutical and biotechnology partners during the BIO International Convention 2026 in San Diego ( https://nnw.fm/APy2D ).

Disseminated on behalf of Onco-Innovations Ltd. (CBOE CA: ONCO) (OTCQB: ONNVF) and may include paid advertising.

Professionals and executives from clinical, legal, regulatory, and operational sectors are invited to attend the 7th Clinical Trial Agreements Summit, to be held on Aug. 27-28, 2026, at the Sonesta Philadelphia Rittenhouse Hotel in Philadelphia, Pennsylvania.

Energy, Oil & Gas Magazine profiles CEO Robert Price as company prepares for October 2026 exploration campaign in East Greenland

Artificial intelligence has become a part of everyday life for millions of people. Tools such as ChatGPT, Claude, and other AI assistants are now used for learning, work, research, and finding information online. While these technologies offer many benefits, a new study suggests that relying too much on AI may have negative effects on critical thinking and independent judgment.

Researchers from King’s College London and McMaster University have made a discovery that could fundamentally change how doctors treat brain cancer. The team identified a molecular pathway that appears critical to cancer’s ability to migrate to the brain.

On Monday, precious metal prices ticked upwards. Gold reached $4,362 an ounce, marking gains of approximately 3.4%. Silver’s price hit $71.2 an ounce, a rally of about 4.7%. We look at some of the key factors that are driving this rally in precious metal prices as this week progresses.

BioMedWire Editorial Coverage: Oncology research is moving through one of its most active stretches in years. DNA Damage Response (“DDR”) inhibitors, a category of drugs that work by blocking cancer cells’ capacity to fix their own damaged DNA, are growing well beyond the poly ADP ribose polymerase (“PARP”) inhibitor that first defined the category. DDR-inhibiting therapies generated an estimated $7 billion-plus in worldwide sales in 2025, and the wider oncology, diagnostics and precision medicine markets are expected to approach about $750 billion by 2030. A fresh wave of inhibitor classes is now taking shape as the next major opportunity. Standing at the leading edge of this shift is Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) ( Profile ), a Canadian clinical-stage oncology company developing ONC010(TM), a nanoparticle-encapsulated PNKP inhibitor designed to target a DNA repair enzyme that participates in several distinct repair pathways. As the industry works toward the next generation of synthetic lethality assets, Onco-Innovations occupies a distinctive niche as it builds out its position within the biopharmaceutical and biotechnology space, alongside other established companies such as Merck & Co. Inc. (NYSE: MRK), Pfizer Inc. (NYSE: PFE), GSK plc (NYSE: GSK) and Gilead Sciences Inc. (NASDAQ: GILD), all of which are focused on…

BioMedWire Editorial Coverage: Multiple sclerosis (“MS”) gradually strips people of command over their own bodies, advancing steadily with no available cure. More than 2.9 million people across the globe are currently living with the disease. But even with generations of scientific study and research, every approved treatment still falls short of one essential objective: bringing the disease to a complete stop. Existing therapies can slow its advance, but none can halt it outright. That shortfall translates into a future of mounting disability for millions of MS sufferers. Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) ( Profile ) is determined working to change that outcome. The company is developing Lucid-MS, a patented, first-in-class drug candidate that approaches the disease from an entirely different angle by directly targeting the myelin sheath that MS destroys; the potential treatment is now preparing to move into phase 2 clinical trials. Quantum BioPharma stands among a group of companies pursuing therapies for neurological, autoimmune and immune-mediated conditions, a group that also includes Novartis AG (NYSE: NVS), Merck & Co. Inc. (NYSE: MRK), TG Therapeutics Inc. (NASDAQ: TGTX) and…

This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising.

Beeline Holdings (NASDAQ: BLNE), a fast-growing digital mortgage platform offering a quicker and easier path to home ownership, was added as a member of the Russell Microcap Index, marking a notable milestone for the digital mortgage company as it attempts to scale its technology-driven lending platform during one of the most challenging housing finance environments in years.

This article has been disseminated on behalf of Onco-Innovations Limited and may include paid advertising.

Cardio Diagnostics Holdings (NASDAQ: CDIO), an AI-powered precision cardiovascular medicine company, announced that Atlas Healthcare Physicians, an independent physician association serving managed care populations across Los Angeles and Orange counties, will provide coverage for the company’s Epi+Gen CHD(TM) and PrecisionCHD(TM) tests for eligible members with prior authorization. The coverage expands access to physician-ordered blood tests designed to assess coronary heart disease risk and support diagnosis and personalized treatment planning.

Massimo Group (NASDAQ: MAMO), a manufacturer and distributor of powersports vehicles and mobility solutions, announced it has terminated its previously proposed acquisition of FST Development Company Limited. The company said that after reviewing its strategic priorities, capital allocation plans and recent development progress, it elected not to proceed with the transaction or the previously contemplated stock-based acquisition structure.

Gaxos.ai (NASDAQ: GXAI) a developer of artificial intelligence applications across multiple industries, announced the completion of the sale of its gaming assets, including its portfolio of mobile games and Gaxos Gaming Labs, to privately held Game Foundry AI. The all-stock transaction was valued at approximately $1.76 million and is intended to support Gaxos’ strategy of focusing resources on its revenue-generating AI businesses and higher-margin commercial opportunities.

Rail Vision (NASDAQ: RVSN) (FSE: C80), a developer of AI-powered railway safety and sensing systems, announced the successful completion of ShuntingYard field testing with Israel Railways. The evaluation was conducted during daily rail yard operations, where locomotive drivers and operational personnel assessed the system’s ability to detect and classify potential obstacles in real time under active and challenging operating conditions. According to the company, feedback from Israel Railways personnel was positive, highlighting the system’s ability to enhance situational awareness during shunting activities.

This article has been disseminated on behalf of Onco-Innovations Limited and may include paid advertising.

This article has been disseminated on behalf of Helus Pharma and may include paid advertising.

This article has been disseminated on behalf of Silvercorp Metals and may include paid advertising.

This article has been disseminated on behalf of Helus Pharma and may include paid advertising.

Greenland Mines (NASDAQ: GRML) is focused on the exploration and development of mineral assets in Greenland. Through its mining division, the company is advancing the Skaergaard Project in southeast Greenland while also pursuing the acquisition of the Sarfartoq rare earth project in southwest Greenland. Together, these assets provide exposure to precious metals, critical metals and rare earth elements within a jurisdiction that has attracted growing interest as governments and industries seek to diversify strategic mineral supply chains.

VERAXA Biotech (NASDAQ: VRXA) an emerging developer of novel cancer therapies, announced it has expanded its laboratory footprint at its existing research and development site in Heidelberg, Germany, under a previously executed long-term lease agreement. The additional space will support planned growth of the company’s R&D team, installation of new laboratory equipment and completion of infrastructure needed to advance future development activities.

Wearable Devices (NASDAQ: WLDS) announced the release of a new white paper outlining how its Mudra neural interface platform could serve as an “intent layer” for agentic artificial intelligence, augmented reality and robotics applications. The paper introduces the company’s proprietary Large MUAP Model (“LMM”), which translates wrist-based nerve and muscle signals into machine-readable “neural tokens” designed to improve intent recognition, reduce user setup requirements and enhance system performance as additional data is collected.

Datavault AI (NASDAQ: DVLT) through its Acoustic Sciences division’s WiSA Technologies, announced that its WiSA E Enterprise wireless audio module has been integrated into Goldhorn’s new Goho LS7 2.0 and 5.1 home audio and karaoke systems. The systems feature 4K Ultra HD projectors and are designed to deliver high-definition stereo and immersive 5.1 surround sound using WiSA’s wireless audio transmission technology, with products now available in China.

This article has been disseminated on behalf of Wheaton Precious Metals Corp. and may include paid advertising.

Disseminated on behalf of ESGold Corp. (CSE: ESAU) (OTCQB: ESAUF) and may include paid advertising.

The search for new cancer therapies has traditionally focused on discovering entirely new drug candidates. While this approach has produced important breakthroughs, it is also expensive, time-consuming and carries a high risk of failure. Increasingly, researchers and biotechnology companies are exploring a complementary strategy: improving the way existing drugs are delivered to patients.

Hallmark Venture Group (OTC: HLLK) announced the completion of a strategic transaction that transforms the company from a shell entity into an operating drone technology business focused on unmanned aerial systems, defense technology and commercial applications. Through the acquisition of a worldwide drone technology platform from South Korea-based Sundori Drone Co., Ltd., the company obtained proprietary technology, software, AI and machine-learning assets, technical documentation and commercialization rights tied to 12 Korean patents, while also securing ongoing engineering support and collaboration agreements.

Gold continues to strengthen its position within the global financial system, with central banks signaling a growing commitment to the precious metal despite record-high prices. According to the latest survey on Central Bank Gold Reserves by the World Gold Council, confidence in gold remains exceptionally strong among reserve managers globally.

Global electric vehicle deployment has accelerated far beyond initial industry projections and forecasts . EV sales reached approximately 21 million units in 2025, reflecting impressive growth trajectories across all markets worldwide. Market penetration shifted dramatically from minimal shares to dominant positions spanning multiple continents.

Researchers at Washington University (WashU) Medicine have conducted a small clinical trial testing a new vaccine against glioblastoma . The formulation was administered to nine patients who had undergone surgery and chemo-radiation therapy to remove their tumors. The results of this study show promise in extending tumor-free survival for a disease that is currently hard to treat.

If you have seen the buildings housing data centers, you may be wondering why the timelines from data center planning to commissioning take years while similarly sized warehouses require weeks or a few months to construct. We explore some specific reasons why setting up a data center can stretch several years before the facility comes online.

A new report published by Wood Mackenzie, a global research company, reveals that producers of metals like aluminum and copper are seeing a huge uptick in the demand of these metals beyond what current estimates suggest.

Consumer electricity expenses dropped significantly in Spain while most European households faced rising power bills following the Middle Eastern conflict disrupting global energy supplies and shipping routes. Monthly cost reductions averaged approximately $11 per household due to renewable infrastructure progressively reducing fossil fuel dependence.

Fresh details have emerged about a series of arson attacks linked to properties associated with UK Prime Minister Sir Keir Starmer, with reports indicating that a Russian-directed network allegedly promised cryptocurrency payments to those involved.

Binance, one of the world’s largest cryptocurrency exchanges, is facing uncertainty in Europe as a key regulatory deadline draws closer. Reports suggest that the company’s application for a license under the European Union’s Markets in Crypto-Assets (MiCA) framework may be rejected in Greece. If that happens and Binance fails to secure approval elsewhere, it could lose the ability to offer its services across the EU starting in July.

Greenland Energy (NASDAQ: GLND) is positioning itself at the intersection of one of the Arctic’s most compelling economic opportunities. Through the company’s Jameson Project in East Greenland, it is pursuing resource exploration in an area that has long attracted geological interest but has seen only limited development. As Greenland seeks to improve its economic future and cut down dependence on external financial support, projects like Jameson highlight the critical role responsible resource development can play in building long-term prosperity.

Onco-Innovations (CBOE CA: ONCO) (OTCQB: ONNVF) announced its inclusion in a BioMedWire editorial examining the growing market for DNA Damage Response inhibitor (“DDRi”) therapies and the next generation of cancer treatments targeting DNA repair pathways. The article highlights the company’s lead candidate, ONC010(TM), a nanoparticle-encapsulated PNKP inhibitor designed to target a key DNA repair enzyme involved in multiple repair mechanisms, positioning Onco-Innovations among emerging developers seeking to advance new synthetic lethality approaches in precision oncology.

Safe Pro Group (NASDAQ: SPAI), has released a demonstration video highlighting its new RoadSight capability, which applies the company’s patented SPOTD (Safe Pro Object Threat Detection) technology to autonomous Unmanned Ground Vehicles (“UGVs”). The video illustrates how Safe Pro’s AI-powered computer vision platform is designed to detect landmines, unexploded ordnance and other explosive threats in real time, complementing the company’s recently announced $1.3 million U.S. Army subcontract to integrate the technology into autonomous UGVs.

This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising.

American Fusion (OTC: AMFN) provided an update after Chief Technology Officer Dr. John Brandenburg presented the company’s Texatron(TM) Fusion Engine(TM) platform at the IEEE International Conference on Plasma Science (“ICOPS”) 2026 on June 22. Management reported strong engagement from researchers and industry professionals attending the conference, with extensive follow-up discussions surrounding the company’s compact fusion technology and its potential role in future energy production.

This article has been disseminated on behalf of Energy Fuels Inc. and may include paid advertising.

Safe Pro Group (NASDAQ: SPAI), announced it has received a $1.3 million U.S. Army subcontract from a leading defense prime contractor to integrate its proprietary AI-powered real-time threat detection technology into autonomous Unmanned Ground Vehicles (“UGVs”). The project will incorporate Safe Pro’s computer vision and machine learning pipeline onboard UGVs to detect explosive threats in real time while supporting on-the-move military operations.

Blockchain Futurist Conference is set to return to Toronto on July 21–22, 2026, bringing together institutions and digital asset leaders to explore emerging advances in finance. The conference will focus on key topics including digital asset regulation, institutional adoption, stablecoins, tokenization, artificial intelligence, compliance, decentralized finance, and digital identity. Featured sessions will include discussions with representatives from organizations such as Bloomberg, JPMorgan, Mastercard, and other industry leaders. Sponsors and partners including AiraPay and Stablecorp will showcase innovations in payments and stablecoin technology, while special programming from organizations such as House of Intelligence and Invest Hong Kong will shine the spotlight on emerging trends in AI, privacy, and global digital asset adoption.

Heart disease has held the grim distinction of being the leading cause of death in the United States for decades, and despite advances in medicine, the problem is getting worse, not better. According to the American Heart Association (“AHA”), cardiovascular disease accounted for more than 940,000 deaths in the United States in 2022, maintaining its position as the nation’s number one killer. Into that persistent and costly healthcare burden steps Cardio Diagnostics Holdings (NASDAQ: CDIO), a Chicago-based precision cardiovascular medicine company that is applying artificial intelligence, epigenetics and genetics to a problem that traditional diagnostic tools have never fully solved: detecting coronary heart disease, including forms that standard methods routinely miss, from a simple blood draw.

American Fusion(TM) (OTC: AMFN), a developer of next-generation fusion energy technologies, recently announced another step in its commercialization strategy with the filing of a new patent application covering innovations expected to be incorporated into future commercial versions of its Texatron(TM) Fusion Engine(TM) platform. According to the company, the application covers architectural and operational innovations currently being evaluated for future generations of the Texatron(TM) Fusion Engine(TM) following completion of Version 9 testing ( https://ibn.fm/57OcR ).

This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising.

This article has been disseminated on behalf of Nevada Organic Phosphate Inc. and may include paid advertising.

NanoViricides, Inc. (NYSE American: NNVC) announced that it has shipped NV-387 Oral Gummies to the Democratic Republic of Congo in preparation for a Phase II clinical trial evaluating the drug as a treatment for MPox. The company said site preparations are being conducted by its contract research organization, Om Sai Clinical Research Pvt. Ltd., and local partners, with patient enrollment and dosing expected to begin following completion of staff training in the coming weeks.

Greenland Mines (NASDAQ: GRML) announced it has awarded a diamond drilling contract to Nordisk Fundering A/S for the 2026 field campaign at its 80%-owned Skaergaard precious and critical metals project in southeast Greenland. The planned program will include approximately 7,500 meters of helicopter-supported diamond core drilling aimed at advancing resource categories, collecting additional metallurgical material and supporting geotechnical studies for potential future open-pit development scenarios.

This article has been disseminated on behalf of SPARC AI Inc. and may include paid advertising.

This article has been disseminated on behalf of Silvercorp Metals and may include paid advertising.

This article has been disseminated on behalf of Onco-Innovations Limited and may include paid advertising.

Nvidia, the technology giant led by CEO Jensen Huang, built its reputation on the advanced chips that helped fuel the rapid rise of AI . Now Huang is betting that the next stage of the AI boom can do more than transform computing. He believes it can help rebuild American manufacturing and strengthen domestic industry.

The United States has reached a critical infrastructure milestone that will enable broader electric vehicle adoption across diverse markets. The Alternative Fuels Data Center notes that charging networks now encompass approximately 250,000 ports distributed at roughly 80,500 sites. Current deployment reflects substantial progress toward long-term sustainability objectives.

Many people save and invest with one primary goal: to protect the value of their hard-earned money over time. However, this has become increasingly challenging in a world of persistent inflation, economic uncertainty, and fluctuating financial markets. A major reason is the nature of modern fiat currencies.

About 90% of men that undergo prostate cancer treatment, and almost 50% of men treated for different kinds of cancer suffer a degree of sexual dysfunction or erectile challenges. Most hardly ever open up about these issues and they suffer in silence. This needn’t be so, because there are many ways through which sexual challenges can be addressed for men with cancer.

On Wednesday, the U.S. Fed completed its latest FOMC meeting with a decision to keep benchmark lending rates at their current level due to uncertainty about inflationary pressures arising from high energy prices due to the Middle East conflict. However, the policymakers signaled that there could be a rate hike later this year if inflation doesn’t slow down.

BioMedWire Editorial Coverage: Cancer research is entering one of its most dynamic periods in decades. The class of drugs known as DNA Damage Response inhibitors, which work by blocking cancer cells’ ability to repair their own damaged DNA, is expanding rapidly beyond its original anchor, the PARP inhibitor. DDRi therapies collectively represented an estimated $7-plus billion in global sales in 2025, and the broader oncology, diagnostics and precision medicine markets are projected to climb to roughly $750 billion by 2030. New inhibitor classes are emerging as the next major wave. Sitting at the forefront of this shift is Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF), ( Profile ) a Canadian clinical-stage oncology company developing ONC010(TM), a nanoparticle-encapsulated PNKP inhibitor that targets a DNA repair enzyme involved in multiple DNA repair pathways. As the field races to find the next generation of synthetic lethality assets, Onco-Innovations occupies a unique space as it strengthens its position in the biopharmaceutical and biotechnology sector, along with other leading companies, such as AstraZeneca plc (NYSE: AZN), Aprea Therapeutics Inc. (NASDAQ: APRE), Boundless Bio Inc. (NASDAQ: BOLD) and Foghorn Therapeutics Inc. (NASDAQ: FHTX), that are focused on developing therapies for serious…

BioMedWire Editorial Coverage: Multiple sclerosis (“MS”) robs people of control over their own bodies — slowly, relentlessly and without a cure. More than 2.9 million people worldwide are living with MS today, and despite decades of research, every approved treatment falls short of the same fundamental goal: stopping the disease cold. Current therapies can slow progression, but they cannot halt it, and for millions of patients, that gap means a future of worsening disability. Now, Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) ( Profile ) is challenging that reality. The company is advancing Lucid-MS, a patented, first-in-class drug candidate that takes a fundamentally different approach by directly targeting the myelin sheath that MS destroys, and this new drug candidate is preparing to enter phase 2 clinical trials. Quantum BioPharma is one of several companies focused on the development and commercialization of therapies for neurological, autoimmune and immune-mediated diseases, including Sanofi (NASDAQ: SNY), Roche Holding AG (OTCQX: RHHBY), Biogen Inc. (NASDAQ: BIIB) and…

Energy capital allocation is undergoing a historic transformation that’s favoring renewable technologies over conventional fossil fuels. According to the International Energy Agency’s latest World Energy Investment analysis, clean power infrastructure has attracted substantially greater funding than traditional energy projects through 2026, marking a fundamental shift in global investment patterns.

Nocera (NASDAQ: NCRA) provided additional details regarding its minority equity investment in CampaignPulse.ai, an artificial intelligence-driven platform being developed to help organizations simulate audience responses, test messaging strategies and evaluate campaign effectiveness before committing resources to real-world deployment. The platform is expected to leverage large language models, predictive analytics and simulation-based modeling to support applications across political campaigns, corporate communications, public affairs, fundraising, investor relations, marketing and reputation management.

A major shift is about to reshape Europe’s crypto sector as the transition period under the Markets in Crypto-Assets (MiCA) regulation ends on July 1. The deadline marks the conclusion of an 18-month grace period that allowed firms previously operating under national registration systems to obtain authorization under the EU’s new regulatory framework.

Artificial intelligence is changing the way people shop online. Businesses are using AI to improve customer service, create product descriptions, recommend products, and automate many parts of ecommerce. While these tools can make shopping more convenient, a new study suggests that AI is also creating new concerns for consumers.

Nightfood Holdings (OTCQB: NGTF) operating through its TechForce Robotics division, was featured in a NetworkNewsAudio Audio Press Release highlighting the growing demand for automation solutions driven by the global buildout of artificial intelligence infrastructure. The editorial notes that major technology companies are expected to invest hundreds of billions of dollars in AI-related infrastructure, creating downstream opportunities for companies providing manufacturing, engineering and precision automation systems.

Exploring the concepts, products and innovations influencing currencies, digital assets and global finance.

Disseminated on behalf of LaFleur Minerals Inc. (CSE: LFLR) (OTCQB: LFLRF) and may include paid advertising.

Exploring the policies, markets and global events influencing currencies and the movement of money worldwide

Xeriant (OTCQB: XERI) announced an upcoming production run of its patented NEXBOARD(TM) composite building panels, marketed under the DUREVER(TM) line of sustainable construction materials. The production campaign follows the recent achievement of Class A ASTM E84 and NFPA 286 fire safety certifications and is intended to fulfill sample requests from multiple leading homebuilders and commercial construction firms evaluating the product for future projects.

M-tron Industries (NYSE American: MPTI) announced a $6.8 million follow-on order from a U.S. Department of Defense contractor supporting multiple counter-unmanned aircraft system (“C-UAS”) radar programs. The order includes several products, including high-performance oven-controlled crystal oscillators, with work scheduled to be performed in Orlando, Florida, through 2027.

This article has been disseminated on behalf of Knight Therapeutics Inc. and may include paid advertising.

This article has been disseminated on behalf of Onco-Innovations Limited and may include paid advertising.